Boston Scientific accounts are for healthcare professionals only.
Ranger is the only drug-coated balloon on a 200cm monorail platform.
Designed specifically to treat the SFA, the exchange port placement optimizes pushability while the reinforced catheter increases stability.
- The only rapid exchange radial-compatible DCB
- The longest radial-compatible DCB with sizes up to 200cm
- Built on the best-in-class Sterling™ platform
- Optimized for pushability with a longer 35cm exchange port and reinforced catheter
Advancing Patient Care Through Innovation in PAD
Dr. Ramzan Zakir shares how embracing evidence-backed technology and transradial access transforms outcomes in interventional cardiology.
Ranger DCB product details
Ranger DCB has a comprehensive matrix and is compatible with various access sites including pedal access1.
| Ranger matrix | 40 mm | 60 mm | 80 mm | 100 mm | 120 mm | 150 mm | 200 mm |
| 4 mm | 5 F | 5 F | 5 F | 5 F | 5 F | 5 F | 5 F |
| 5 mm | 5 F | 5 F | 5 F | 5 F | 5 F | 5 F | 5 F |
| 6 mm | 5 F | 5 F | 5 F | 5 F | 5 F | 5 F | 5 F |
| 7 mm | 6 F | 6 F | 6 F | 6 F | 6 F | 6 F | 6 F |
Over-the wire catheter with working lengths of 80cm, 90cm, 135cm, 150cm, and NEW Monorail 200cm working length and 35cm exchange length
References:
1. Boston Scientific Data on File. Ranger Catheter Competitive Testing Report, 92517674. Ranger diameters ≤6mm, testing done with Terumo GLIDESHEATH SLENDER™ 5F.4. COMPARE Clinical Trial 1-Year Results presented by Sabine Steiner, MD. LINC 2020. K-M Primary Patency = 88.4%. RANGER II SFA Pivotal Trial 1-Year Results presented by Marianne Brodmann. LINC 2020. K-M Primary Patency = 89.8%.